LekoskopLekoskop
EN All changes
Medicine recalls and shortages › New approvals › 27 Sep 2024
MHRA approval

first medicine

Published on 27 Sep 2024 · source: MHRA — Medicines and Healthcare products Regulatory Agency
The Medicines and Healthcare products Regulatory Agency (MHRA) has on 25 September approved leniolisib phosphate (Joenja) to treat a rare immune disease known as activated phosphoinositide 3-kinase d…
MHRA announcement ↗ All events: first medicine

What this means

The MHRA has announced the approval of a medicine or a new indication in the UK. Approval does not mean the product is already available on the NHS: NICE appraisal and commissioning may follow.

Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has on 25 September approved leniolisib phosphate (Joenja) to treat a rare immune disease known as activated phosphoinositide 3-kinase delta syndrome or APDS in adults and adolescents aged 12-years-old and older who weigh 45kg or more. 

Tracked from information published by the MHRA and the NHSBSA. This information is for guidance only and does not replace advice from your doctor or pharmacist.